Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Adult
Humans
Metformin
/ pharmacology
Hypoglycemic Agents
/ pharmacology
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ pharmacology
Metabolic Syndrome
/ drug therapy
Glycated Hemoglobin
Prospective Studies
Glucagon-Like Peptide 1
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
4-dipeptidyl peptidase inhibitors
DPP-4I
GLP-1RA
Glucagon-like peptide 1 agonists
Metabolic syndrome
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
08
02
2023
revised:
15
03
2023
accepted:
15
03
2023
medline:
3
4
2023
pubmed:
20
3
2023
entrez:
19
3
2023
Statut:
ppublish
Résumé
To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.
Identifiants
pubmed: 36934556
pii: S0753-3322(23)00349-9
doi: 10.1016/j.biopha.2023.114561
pii:
doi:
Substances chimiques
Metformin
9100L32L2N
Hypoglycemic Agents
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glycated Hemoglobin
0
Glucagon-Like Peptide 1
89750-14-1
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114561Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement JS-S reports serving on the board of and receiving grant support through his institution from the International Nut and Dried Fruit Council, and Eroski Foundation. Reports serving in the Executive Committee of the Instituto Danone Spain and on the Scientific Committee of the Danone International Institute. He has received research support from Patrimonio Comunal Olivarero, Spain; and Borges S.A., Spain. Reports receiving consulting fees or travel expenses from Danone; Eroski Foundation, Instituto Danone - Spain, and Abbot Laboratories.